Search

Your search keyword '"Mazieres, B"' showing total 346 results
Start Over Author "Mazieres, B"
346 results on '"Mazieres, B"'

55. Multiple intraosseous meningiomas

Author

El Mahou, S., primary, Popa, L., additional, Constantin, A., additional, Jamard, B., additional, Cantagrel, A., additional, Mazieres, B., additional, and Laroche, M., additional

Published
2005
Full Text
View/download PDF

66. Prevalence of symptomatic hip and knee osteoarthritis: a two-phase population-based survey 1.

Author

Guillemin, F., Rat, A.C., Mazieres, B., Pouchot, J., Fautrel, B., Euller-Ziegler, L., Fardellone, P., Morvan, J., Roux, C.H., Verrouil, E., Saraux, A., and Coste, J.

Abstract

Summary: Objective: Osteoarthritis (OA) epidemiologic data are scarce in Europe. To estimate the prevalence of symptomatic knee and hip OA in a multiregional sample in France. Design: A two-phase population-based survey was conducted in six regions in 2007–2009. On initial phone contact using random-digit dialing, subjects 40–75 years old were screened with a validated questionnaire. Subjects screened positive were invited for ascertainment: physical examination and hip and/or knee radiography (Kellgren–Lawrence grade≥2). Multiple imputation for data missing not-at-random was used to account for refusals. Results: Of 63,232 homes contacted, 27,632 were eligible, 9621 subjects screened positive, 3707 participated fully in the ascertainment phase, and 1010 had symptomatic OA: 317 hip, 756 knee. Hip OA prevalence according to age class ranged from 0.9% to 3.9% for men and 0.7–5.1% for women. Knee OA ranged from 2.1% to 10.1% for men and 1.6–14.9% for women. Both differed by geographical region. The hip and knee standardized prevalence was 1.9% and 4.7% for men and 2.5% and 6.6% for women, respectively. Conclusions: This confirmed the feasibility of using a screening questionnaire for eliciting population-based estimates of OA. In France, it increases with age and is greater among women above the age of 50. The geographical disparity of hip and knee OA parallels the distribution of obesity. Study registration ID number 906297 at http://www.clinicaltrials.gov/. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

73. Decreased Peripheral Blood T Cell Cytokine Gene Expression in Rheumatoid Arthritis.

Author

Loubet-Lescoulie, P., Constantin, A., Mazieres, B., Tkaczuk, J., de Preval, C., and Cantagrel, A.

Subjects
T cells, RHEUMATOID arthritis, POLYMERASE chain reaction, GENE expression, IMMUNOLOGY
Abstract

Currently, few informations are available about spontaneous production of T cell cytokines in rheumatoid arthritis (RA) peripheral blood (PB), because these cytokines are generally under the detection threshold of ELISAs. Because the Th1/Th2 balance could help to determine the outcome of RA, we used a sensitive and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) method to mesure spontaneous T cell production of IL-2, IL-4, IL-10, and IFN-γ mRNAs using unstimulated PBMC from 25 active RA patients, not taking any DMARDs for at least 6 weeks, and 19 healthy controls. Spontaneous IL-2 and IL-4 mRNA expressions are significantly lower in RA patients compared to healthy controls. Levels of IL-10 and IFN-γ are similar in the two groups. No correlation was found between cytokine mRNA levels and clinical parameters. Spontaneous IL-4 and IL-10 mRNA levels are respectively correlated to the number of CD4 + T cells and to the number of monocytes in PB. After in vitro stimulation, IFN-γ mRNA production by RA PBMC is significantly decreased. Most of the patients cannot be classified as having a T cell cytokine type 1 or type 2 secretion pattern in PB. IL-2 and IL-4 mRNAs in PB of active RA are produced at a low spontaneous level and the response to in vitro activation by mitogen is weak. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

76. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study.

Author

Mazieres, B, Combe, B, Phan Van, A, Tondut, J, and Grynfeltt, M

Abstract

OBJECTIVE: To assess the efficacy and safety of chondroitin sulfate (CS) 1 g/day per os compared to placebo, in a double blind, randomized, parallel group study, with 3 months treatment followed by a 3 month posttreatment period, in patients with femorotibial osteoarthritis (OA). METHODS: The main criterion was the functional handicap assessed by Lequesne's algofunctional index (AFI). Secondary efficacy criteria were: self-assessed pain with activity and at rest, self-assessed impact of OA on daily living, patient and physician assessed overall change in patient state since the previous visit, and daily NSAID and analgesic consumption, all evaluated monthly. The main analysis was performed on the intent-to-treat (ITT) population at treatment endpoint compared to baseline (Day 0). RESULTS: The ITT efficacy data set comprised 130 patients (63 in CS group and 67 in placebo group). At treatment endpoint, the AFI showed greater but nonsignificant improvement in the CS than in the placebo group. Improvement became significant (p = 0.02) in the completer population (n = 114). In the ITT population, all variables tended towards greater improvement in the CS than the placebo group. In the completer population, pain at rest also significantly decreased in the CS group compared to the placebo group (p = 0.03), and, one month after treatment, CS had a significantly higher persistent effect than placebo on the AFI (p = 0.01), pain with activity (p = 0.001), physician assessed patient state (p = 0.05), and most other efficacy criteria. Adverse event rates did not differ significantly. CONCLUSION: We observed a trend towards efficacy of CS 1 g/day compared to placebo with good tolerability after 3 month treatment, and persistent efficacy one month posttreatment. Further investigations are required to confirm this trend.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results